Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[41] Amoxicillin/clavulanic acid: Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis.Thorax. 2010 Jul;65Suppl 1:i1-58. http://www.ncbi.nlm.nih.gov/pubmed/20627931
Amoxicllin/clavulanic acid: NICD pneumococci susceptibility data for amoxicillin for the period 2005-2014 [E-mail communication]
Amoxicillin/clavulanic acid: Kiffer CR, Pignatari AC. Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens. BMC Infect Dis. 2011 Oct 25;11:286. http://www.ncbi.nlm.nih.gov/pubmed/22026724
Amoxicillin/clavulanic acid: Allegra L, Blasi F, de Bernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther. 2001;14(2):149-55. http://www.ncbi.nlm.nih.gov/pubmed/11273797
Amoxicillin/clavulanic acid, oral: Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Dec 12;12:CD010257. http://www.ncbi.nlm.nih.gov/pubmed/23235687